Aytu bioscience announces positive clinical results from healight(tm) pilot study in sars-cov-2 patients

Data indicate endotracheal uva light catheter therapy reduces sars-cov-2 viral load and improves clinical outcomes in mechanically ventilated sars-cov-2 patients  englewood, co / accesswire / march 8, 2021 / aytu bioscience, inc. (nasdaq:aytu), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs, announced today that data from a first in-human, open label, clinical trial in sars-cov-2 patients has been released. the pre-print publication titled "endotracheal application of ultraviolet a light in critically ill severe acute respiratory syndrome coronavirus-2 patients: a first-in-human study" concluded that endotracheal uva light treatment was associated with a significant reduction of sars-cov-2 viral load and improvement in who clinical severity scores.
AYTU Ratings Summary
AYTU Quant Ranking